SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia ®, conditionally approved for CID, to regulatory approval and ...

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia ®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple ...

“Jaguar’s primary objective for Canalevia (crofelemer delayed-release tablets) is to identify a partner with which to collaborate to achieve our three parallel goals for the drug: Obtain approval in ...

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...

Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If ...

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...

“I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of ...